Gastroenterologist and Inflammatory Bowel Disease specialist @BIDMC_GI, GI @NYUlangone @BellevueHosp, IM @BMCimRES, opinions my own
Boston, MA
Joined June 2017
- Tweets260
- Following881
- Followers654
- Likes1.5K
Samantha Zullow retweeted
Research often lumps young adults into the 18–65 age group, ignoring crucial developmental and physiological differences. This leads to misguided treatment decisions and missed chances to improve long-term outcomes for conditions like #IBD.
Read more: sciencedirect.com/science/ar…
Samantha Zullow retweeted
Colorectal cancer is the #1 cause of cancer death in men under 50. This is why #45istheNew50.
Our team at #BIDMC_GI is here to help schedule your screening.
📞 617-754-8888
💻 bit.ly/3wGnK5c
#ColorectalCancerAwarenessMonth
Samantha Zullow retweeted
Stay proactive about your health! If you have IBD, you're at a higher risk of colorectal cancer. Talk to our team today about getting your screening.
📞 617-754-8888
💻 bit.ly/3wGnK5c
#ColorectalCancerAwarenessMonth
Samantha Zullow retweeted
Common scenario in IBD clinic answered by @sidbarritt4
💎 Isolated HBcAb pts on anti-TNF agents are considered low risk and do not necessarily require HBV prophylaxis
@DCharabaty @IBDConference #AIBD2024
Samantha Zullow retweeted
One of the best summary slides at #AIBD2024 by Dr. Marla Dubinsky:
Specific scenarios for positioning IBD therapy 💉💊
And as Dr. @MLongMD said: “JAKs for joints, ILs for skin”
@IBDConference @DrCoreySiegel @MRegueiroMD @CCYANetwork
Thank you for a wonderful conference 🔥🔥
Excellent UP treatment algorithm; consider use of topical/rectal tacrolimus before moving on to other advanced therapy. Consider etrasimod given UP subgroup in clinical trials. #AIBD2024 @IBDConference
#AIBD2024 mod-severe UP subgroup seen in etrasimod study; improved outcomes compared to more extensive colitis @IBDConference @mchiorean4
#AIBD2024 clinical trials stopped early due to significant improvement on tacrolimus for refractory UP. Significant clinical and endoscopic improvement seen. @IBDConference @mchiorean4
Live from #AIBD2024: Some non-invasive IBD biomarkers are less reliable in ulcerative proctitis including intestinal ultrasound and fecal calprotectin @IBDConference @mchiorean4
UP risk factors for progression; it is important to explain to patients they have a risk for extension of disease. Up to 20% of pateints require treatment intensification to an advanced therapy
#AIBD2024 @IBDConference
Looking forward to presenting on April 1st about transition from peds to adult GI care for people with IBD! Hope to see you there @CCYANetwork @CCfdnNewEngland @PediatricIBD #GITwitter #IBD
There is still time to register for MyIBD Learning Patient & Caregiver Education Conference on April 1st. We have an excellent line up of presentations. Tickets are $10 and scholarships are available!
View all of the details here: bit.ly/3TuvChC
Samantha Zullow retweeted
Our Meta‐analysis is out on @APandT The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease onlinelibrary.wiley.com/doi/… - proactive TDM showing significant benefits! @Jonathansegal85 @Dr_Dee_Kumar @GastroMJB @JonnyBlackwell – at South East, England
Great advice for any #GI fellows interested in #IBD fellowship! Reach out to me if you're interested in @BIDMC_GI for IBD fellowship in the future.
📣 Calling all future #IBD fellows!
🍁 Check out our new article in the FALL issue of #ACGMagazine @AmCollegeGastro
Big thank you to our incredible faculty and fellows for their insightful, entertaining and inspiring advice! #BOOM 🔥🫶🏻🌟
⬇️ MUST DO’S for #IBD fellowship! 1/
Samantha Zullow retweeted
In this article, @IBD_Houston examines safety data on ustekinumab in 🤰. In this cohort of 39 #IBD pregnancies:
🚫 no specific safety concerns with maternal ustekinumab
🚫no congenital anomalies were reported in newborns
doi.org/10.1093/crocol/otac0…
Samantha Zullow retweeted
Results from PAPooSE group on 82 pregnancies among 77 IBD stoma pts. These are high risk pts needing MFM monitoring. @MySMFM @ColorectalDis onlinelibrary.wiley.com/doi/…
-->73% C section (24% emergent)
-->24% stoma complication
-->7.5% postpartum hemorrhage
--> 3/77 had bladder injury
Samantha Zullow retweeted
New article @HarvardHealth on #Familyplanning 🫃with #IBD:
▶️Remission before conception is🔑
▶️Assemble your care team 👨⚕️👩⚕️🧑⚕️
▶️Make sure💉up-to-date, discuss IBD💊 with your👩⚕️👨⚕️
#NisaDesai @BIDMC_GI @BIDMC_Medicine
rb.gy/oazivw
Samantha Zullow retweeted
Congratulations to our 13 #BIDMCGI graduates of the Class of 2022! We are so proud of all you have accomplished - in clinic, in endoscopy, through your research, education, & more - you are clinicians of the highest order and we can’t wait to see what you will accomplish next! 🌟
Samantha Zullow retweeted
(1/13)📢 New med option for mod to severe Crohn's disease:
Risankizumab-rzaa (Skyrizi) - IL23 antagonist
🏥 Induction: 600 mg IV @ wk 0, 4, 8 (1 hour)
💉Maintenance: 360 mg @ wk 12, then q8 weeks [single-dose prefilled cartridge]
☑️ EIM: psoriatic arthritis, plaque psoriasis
Samantha Zullow retweeted
This #RCT evaluated infliximab withdrawal in pts with #Crohns disease in remission on infliximab maintenance therapy. Time to relapse was significantly shorter among patients who discontinued IFX than those who continued therapy. eviden.cc/3xOBtVG
#GITwitter #MedTwitter
ALT Figure 2A, "Time to Relapse in Patients with Crohn’s Disease in Combined Remission Continuing or Discontinuing Infliximab Therapy," from the NEJM Evidence Original Article, "Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease," by Sine Buhl, MD, et al.